Public Reporting


ACO Name and Location

MD Valuecare, LLC
8001 Franklin Farms Drive, Suite 130
Richmond, VA 23229

ACO Primary Contact

Shannon Lodge, ACO Administrator
8001 Franklin Farms Drive, Suite 130
Richmond VA 23229
[email protected]

Organizational Information

ACO Participants

“(ACO participants are not in a joint venture)”
Chickahominy Family Practice

Commonwealth Primary Care

Dominion Medical Associates

Virginia Diabetes and Endocrinology

ACO Participants in Joint Ventures Between ACO Professionals and Hospitals


ACO Governing Body

Voting Member and Vice Chair (11.11%)
Other Representative

Dr. John Kowalski

Dr. Damian Covington

Greg Spruill

Voting Member (11.11%)
Medicare Beneficiary Representative

Dr. Dave Taminger

Dr. Steve Young

Dr. Ken Zelenak

Dr. Shea Puttkammer

Voting Member (11.11%)
ACO Participant Representative, Virginia Diabetes and Endocrinology

Key Clinical and Administrative Leadership

Dr. Ken Zelenak, MD

Medical Director
Quality Assurance/Improvement Officer

Shannon Lodge

ACO Executive/Compliance Official

ACO Committees and Committee Leadership

Quality Committee: Dr. Ken Zelenak, Chair

Managing Committee: Rachel Downey, Chair

Specialist Mobilization Committee: Dr. Mark Monahan, Co-Chair and Dr. Johnny Wong, Co-Chair

Types of ACO Participants, or Combinations of Participants, that Formed the ACO

Network of individual practices of ACO professionals.

Shared Savings and Losses

Amount of Shared Savings and Losses

Third Agreement Period

  • Performance Year 2020, $1,894,328

Second Agreement Period

  • Performance Year 2019, $0
  • Performance Year 2018, $0
  • Performance Year 2017, $3,701,488

First Agreement Period

  • Performance Year 2016, $1,809,663
  • Performance Year 2015, $0
  • Performance Year 2014, $0

How Shared Savings Are Distributed

Third Agreement Period

Performance Year 2020

  • Proportion invested in infrastructure: 25%
  • Proportion invested in redesigned care processes/resources: 10%
  • Proportion of distribution to ACO participants: 65%

Second Agreement Period

Performance Year 2019 – N/A
Performance Year 2018 – N/A
Performance Year 2017

  • Proportion invested in infrastructure: 41%
  • Proportion invested in redesigned care processes/resources: 10%
  • Proportion of distribution to ACO participants: 49%

First Agreement Period

Performance Year 2016

  • Proportion invested in infrastructure: 100%
  • Invested in redesigned care processes/resources: 0%
  • Proportion of distribution to ACO participants: 0%

Performance Year 2015 – N/A
Performance Year 2014 – N/A

Quality Performance Results

2020 Quality Performance Results:

Measure NumberMeasure NameYour ACO Performance RateCurrent Year Mean Performance Rate (SSP ACOs)
ACO-43Ambulatory Sensitive Condition Acute Composite (AHRQ Prevention Quality Indicator (PQI #91)) *.63.95
ACO-13Falls: Screening for Future Fall Risk97.3984.97
ACO-14Preventive Care and Screening: Influenza Immunization92.8276.03
ACO-17Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention86.4981.67
ACO-18Preventive Care and Screening: Screening for Depression and Follow-up Plan90.9771.46
ACO-19Colorectal Cancer Screening83.7472.59
ACO-20Breast Cancer Screening79.8474.05
ACO-42Statin Therapy for the Prevention and Treatment of Cardiovascular Disease87.2783.37
ACO-27Diabetes: Hemoglobin A1c Poor Control (>9%)*8.9014.70
ACO-28Controlling High Blood Pressure78.0272.87

For Previous Years’ Financial and Quality Performance Results, please visit

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low sample size. The Centers for Medicare & Medicaid Services (CMS) also waived the requirement for ACOs to field a CAHPS for ACOs survey for PY 2020 through the Physician Fee Schedule Final Rule for Calendar Year 2021. Additionally, CMS reverted ACO-8 Risk-Standardized, All Condition Readmission and ACO-38 Risk-Standardized Acute Admission Rates for Patients with Multiple Chronic Conditions to pay-for-reporting, given the impact of the coronavirus disease 2019 (COVID-19) public health emergency (PHE) on these measures.

Fraud and Abuse Waivers

ACO Participation Waiver:

ACO Participation Waiver: The following information describes each arrangement for which our ACO seeks protection under the ACO Participation Waiver, including any material amendment or modification to a disclosed arrangement.

Parties to the arrangement: MD Valuecare, LLC and Laboratory Corporation of America Holdings
Date of arrangement: June 1, 2021
Items, services, goods, or facility provided: Grants to incorporate data analytics platforms to facilitate care coordination and promote outcomes of care. Incorporate Lab Corp’s lab data into clinical data to provide a more robust view of the ACO’s patient population.
Date and nature of any amendments to the arrangement, if applicable: N/A